Galderma receives FDA Complete Response Letter for RelabotulinumtoxinA
UNVERIFIED·Primary source · Financial Post
Galderma received a Complete Response Letter (CRL) from the FDA regarding its BLA for RelabotulinumtoxinA.
The CRL cites observations during a manufacturing site inspection and analytical method optimization.
The company plans to address these observations through continued dialogue with the FDA.
Key Facts
01
01 — What / Thesis
Galderma receives FDA Complete Response Letter for RelabotulinumtoxinA
02
02 — Who / Subject
Galderma
03
03 — Where / Locus
United States
04
04 — When / Temporality
June 30, 2026
AI Verification Note
This article is generated by cross-referencing multiple sources and official announcements. Parts relying solely on testimony or reporting are reflected in the confidence score; content and assessment are updated as new information is confirmed.
